Physician profile

Mark Clinger

Family Medicine · Nampa, ID

NPI 1699769471

$2,472.78

in general payments reported to CMS, 2019-2025

29 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$82.57

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $341.60 2019-2020
Abbvie INC. $321.78 2021-2022
Astrazeneca Pharmaceuticals LP $263.83 2019-2022
Pfizer INC. $238.12 2019-2022
Abbott Laboratories $184.02 2020-2022
Allergan, INC. $132.56 2019
Novo Nordisk INC $96.38 2019-2022
Merck Sharp & Dohme LLC $93.14 2019-2020
Boston Scientific Corporation $82.57 2023
Lilly USA, LLC $79.16 2019-2022
Astellas Pharma US INC $77.75 2019-2022
E.R. Squibb & Sons, L.L.C. $65.05 2019-2022
Antares Pharma, INC. $60.70 2022
Sanofi-Aventis U.S. LLC $60.46 2019-2022
Boehringer Ingelheim Pharmaceuticals, INC. $55.83 2019-2022
Show all 29 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark Clinger

$2,472.78

in general payments reported 2019-2025

Years
2019-2023
Top company
Amgen INC.

https://glasscript.com/doctor/639451/mark-clinger

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.